These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8615955)

  • 21. Off-label uses of drugs and medical devices: should the FDA crack down?
    Margolis RE
    Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
    [No Abstract]   [Full Text] [Related]  

  • 22. The issue of extralabel drug use.
    Kennedy JA
    J Am Vet Med Assoc; 1997 Dec; 211(11):1354. PubMed ID: 9394877
    [No Abstract]   [Full Text] [Related]  

  • 23. Off-label drugs: question your doctor.
    Consum Rep; 2007 Jun; 72(6):47. PubMed ID: 17632948
    [No Abstract]   [Full Text] [Related]  

  • 24. A turbulent year at the agency.
    Ratner M
    Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
    [No Abstract]   [Full Text] [Related]  

  • 25. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 26. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 27. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 28. Understanding and utilizing qualitative research.
    Atchison KA
    J Dent Educ; 1996 Aug; 60(8):716-20. PubMed ID: 8708146
    [No Abstract]   [Full Text] [Related]  

  • 29. Qualitative research in dentistry.
    Stewart K; Gill P; Chadwick B; Treasure E
    Br Dent J; 2008 Mar; 204(5):235-9. PubMed ID: 18327186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premarket notifications of new dietary ingredients--a ten-year review.
    McGuffin M; Young AL
    Food Drug Law J; 2004; 59(2):229-44. PubMed ID: 15318394
    [No Abstract]   [Full Text] [Related]  

  • 31. Using research for clinical decision-making: the elements of a research report.
    McCann AL; Schneiderman ED
    J Contemp Dent Pract; 2002 Feb; 3(1):74-84. PubMed ID: 12167915
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA seeks to clear up confusion about compounding.
    J Am Vet Med Assoc; 2003 Oct; 223(8):1103, 1106. PubMed ID: 14584731
    [No Abstract]   [Full Text] [Related]  

  • 35. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
    Heymann LA
    Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
    [No Abstract]   [Full Text] [Related]  

  • 36. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 37. New FDA guidance documents.
    Bradshaw ST
    Food Drug Law J; 2007; 62(2):429-31. PubMed ID: 17632971
    [No Abstract]   [Full Text] [Related]  

  • 38. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 39. Copycat papers.
    Pitt Ford TR
    Br Dent J; 2000 Nov; 189(9):469. PubMed ID: 11104095
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation programs at the American Dental Association.
    Wozniak WT
    J Clin Dent; 1995; 6(3):170-3. PubMed ID: 8615958
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.